Search

Search Results

• 

  Methotrexate in the therapeutic pathway of patients with psoriasis. Analysis of clinical practice data and comparison with guidelines

  Valeria Corazza, Francesco Cusano, Ornella De Pità, Luigi Rossi, G. Giovanni Virno

  28-12-2021

  https://doi.org/10.4081/dr.2022.9454

  4113

  PDF: 666

  APPENDIX: 172

  HTML: 15
• 

  Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

  Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  19-05-2023

  https://doi.org/10.4081/dr.2023.9692

  1057

  PDF: 546

  HTML: 19

• Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

  Alba Guglielmo, Maria Ludovica Deotto , Luigi Naldi , Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi

  13-09-2023

  https://doi.org/10.4081/dr.2023.9839

  2689

  PDF: 982

  HTML: 31

• Nightmares caused by isotretinoin in treating hidradenitis suppurativa: a case report and clinical insights

  Fawaz Aljehani, Shumukh Alqahtani, Sara Alharbi, Seham Alsulami

  06-12-2024

  https://doi.org/10.4081/dr.2024.10171

  1520

  PDF: 432

  HTML: 31
• 

  Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

  Martina Vispi, Teresa Corradin, Camilla Peccianti, Luca Feci, Laura Casini, Chiara Pisani, Susanna Fabbroni, Paola Corsetti, Margherita Croatto, Michele Pellegrino

  25-06-2020

  https://doi.org/10.4081/dr.2020.8642

  1352

  PDF: 751

  HTML: 8
• 

  Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus

  Martina Burlando, Elena Campione, Aldo Cuccia, Giovanna Malara, Luigi Naldi, Francesca Prignano, Leonardo Zichichi

  29-12-2022

  https://doi.org/10.4081/dr.2023.9613

  1777

  PDF: 519

  HTML: 75

• Treatment satisfaction among patients with psoriasis in Saudi Arabia

  Mahdi Aldhafiri, Rahaf Almutairi, Reem Albejais, Asma Almubark, Hussain Alwesaibie, Mohammed Albesher, Manayer Almustihi

  15-04-2024

  https://doi.org/10.4081/dr.2024.9967

  1039

  PDF: 553

  HTML: 29

• Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

  Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti

  01-07-2025

  https://doi.org/10.4081/dr.2025.10315

  536

  PDF: 262

  HTML: 13
• 

  Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

  Dimitris Rigopoulos, Aikaterini Patsatsi, Christina Antoniou, Dimitrios Sotiriadis, Angeliki Roussaki-Schulze, Nadia Boubouchairopoulou, Ioannis Skiadas, Vasillios Tsekouras, Ana Cristina Hernandez Daly

  21-11-2022

  https://doi.org/10.4081/dr.2022.9265

  1531

  PDF: 450

  HTML: 27
• 

  Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

  Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

  17-03-2022

  https://doi.org/10.4081/dr.2022.9282

  1162

  PDF: 825

  HTML: 41

• Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

  Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

  11-11-2024

  https://doi.org/10.4081/dr.2024.10140

  989

  PDF: 521

  SUPPLEMENTARY MATERIAL: 154

  HTML: 16

• Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

  Paolo Dapavo, Matteo Megna, Marina Talamonti

  09-08-2024

  https://doi.org/10.4081/dr.2024.9999

  1739

  PDF: 669

  HTML: 94
• 

  Erythrodermic psoriasis treated with apremilast

  John Arcilla, Daniel Joe, Johnathan Kim, Yohanan Kim, VuAnh N. Truong, Navin Jaipaul

  19-09-2016

  https://doi.org/10.4081/dr.2016.6599

  2122

  PDF: 964

  HTML: 600

• Refractory pityriasis rubra pilaris treated with abrocitinib

  Filip Rob

  09-01-2025

  https://doi.org/10.4081/dr.2025.10105

  406

  PDF: 273

  HTML: 11

• Natural language processing of online support group postings reveals patients’ perspectives on strategies for managing psoriasis

  Karan Rajalingam, Phillip M. Johansen, Nicole J. Levin, Jerry Qi, Oge Marques

  11-09-2023

  https://doi.org/10.4081/dr.2023.9824

  884

  PDF: 543

  HTML: 32

• Acute generalized exanthematous pustulosis triggered by dupilumab

  Caterina Mariarosaria Giorgio, Gaetano Licata, Giuseppe Argenziano, Vittorio Tancredi, Anna Balato, Eugenia Veronica Di Brizzi

  23-07-2025

  https://doi.org/10.4081/dr.2025.10219

  388

  PDF: 260

  HTML: 0
• 

  Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data

  Aikaterini Kyriakou, Anastasia Trigoni, Nikiforos Galanis, Dimitrios Sotiriadis, Aikaterini Patsatsi

  01-10-2018

  https://doi.org/10.4081/dr.2018.7859

  1980

  PDF: 1056

  HTML: 63
• 

  Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications

  Vasiliki Tasouli-Drakou, May Nguyen, Hannah Guinn, Omron Hassan, Sneha Butala, Sheshanna Phan

  21-11-2022

  https://doi.org/10.4081/dr.2022.9492

  1686

  PDF: 679

  HTML: 85

• Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab

  Angela Fico, Edoardo Mortato, Claudia Paganini, Marina Talamonti, Cosimo Di Raimondo, Dionisio Silvaggio, Luca Bianchi, Marco Galluzzo

  30-05-2025

  https://doi.org/10.4081/dr.2025.10414

  665

  PDF: 384

  HTML: 16
• 

  Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

  Martina Burlando, Mattia Fabio Molle, Emanuele Cozzani, Aurora Parodi

  14-03-2022

  https://doi.org/10.4081/dr.2022.9091

  2625

  PDF: 632

  HTML: 6
• 

  Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

  Nicoletta Bernardini, Nevena Skroza, Giovanni Rossi, Alessandra Mambrin, Ersilia Tolino, Federica Marraffa, Martina Caviglia, Antonio Di Guardo, Salvatore Volpe, Ilaria Proietti, Concetta Potenza

  21-11-2022

  https://doi.org/10.4081/dr.2022.9447

  1306

  PDF: 405

  HTML: 45

• Anisakis simplex and urticaria. What we know about its real incidence and management in dermatological settings?

  Sanja Javor, Donatella Bignardi, Matteo Borro, Cesare Massone

  29-08-2023

  https://doi.org/10.4081/dr.2023.9819

  1075

  PDF: 685

  HTML: 14

• Does the response to bimekizumab vary according to previous therapy with methotrexate versus cyclosporine?

  Ilaria Salvi, Alexandra M. G. Brunasso, Franco Castelli, Andrea Michelerio, Paolo Pella, Marco Rubatto, Paolo Dapavo, Emanuele Cozzani, Martina Burlando

  20-03-2026

  https://doi.org/10.4081/dr.2026.10236

  215

  PDF: 149

• Skin-directed therapy and biologic response modifiers in mycosis fungoides

  Vieri Grandi, Virginia Alba Colantuono, Nicola Pimpinelli

  07-05-2024

  https://doi.org/10.4081/dr.2024.9926

  591

  PDF: 573
• 

  Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature

  Pablo Santa María, Fernando Valenzuela, Claudia Morales, Raul De la Fuente, Roberto Cullen

  11-10-2017

  https://doi.org/10.4081/dr.2017.7079

  1377

  PDF: 662

  HTML: 142